Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 8/20 | 0.43 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | NPY2R | P49146 | 1/20 | 0.42 |
| ▸ | NPY4R | P50391 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24829476 | 0.94 | FURIN (0.47) | CTSLSIRT2SIRT1SIRT3GRIA1 | |
| SCHEMBL21569760 | 0.94 | FURIN (0.47) | CTSLSIRT2SIRT1SIRT3GRIA1 | |
| SCHEMBL22702533 | 0.92 | NPY5R (0.47) | CTSLSIRT2SIRT1SIRT3GRIA1 | |
| SCHEMBL23355149 | 0.92 | CTSL (0.42) | CTSLSPHK1SIRT2SIRT1SIRT3 | |
| SCHEMBL22746601 | 0.92 | MMP3 (0.43) | SPHK1NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL21754507 | 0.91 | GRIA1 (0.44) | CTSLSIRT2SIRT1SIRT3GRIA1 | |
| SCHEMBL23515087 | 0.91 | SIRT2 (0.46) | CTSLSIRT2SIRT1SIRT3GRIA1 | |
| SCHEMBL24591892 | 0.90 | SIRT2 (0.46) | CTSLSIRT2SIRT1SIRT3GRIA1 | |
| SCHEMBL27351219 | 0.90 | FURIN (0.39) | SPHK1NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL27432486 | 0.90 | FAP (0.46) | CTSLSIRT2SIRT1NPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701427-B2 | Diels-alder conjugation methods | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701427-B2 | Diels-alder conjugation methods | GLUL, TGM2, GLS | CTSL 3164/4885SPHK1 4036/4885SPHK2 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.